179,300 Shares in Protalix BioTherapeutics, Inc. $PLX Acquired by OMERS ADMINISTRATION Corp

Key Points

• OMERS ADMINISTRATION Corp acquired a new stake in Protalix BioTherapeutics, purchasing 179,300 shares valued at approximately $459,000, representing about 0.23% of the company.
• Several institutional investors significantly increased their positions in Protalix BioTherapeutics, with Northern Trust Corp boosting its holdings by an impressive 1,299.4% in the 4th quarter.
• Protalix BioTherapeutics' stock rating was recently downgraded from "strong-buy" to "buy," despite having an average rating of "Buy" and a consensus price target of $15.00.

OMERS ADMINISTRATION Corp bought a new stake in Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 179,300 shares of the company's stock, valued at approximately $459,000. OMERS ADMINISTRATION Corp owned approximately 0.23% of Protalix BioTherapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Squarepoint Ops LLC lifted its position in Protalix BioTherapeutics by 33.4% in the fourth quarter. Squarepoint Ops LLC now owns 73,940 shares of the company's stock worth $139,000 after buying an additional 18,522 shares during the last quarter. Northern Trust Corp lifted its position in Protalix BioTherapeutics by 1,299.4% in the fourth quarter. Northern Trust Corp now owns 731,742 shares of the company's stock worth $1,376,000 after buying an additional 679,451 shares during the last quarter. Millennium Management LLC lifted its position in Protalix BioTherapeutics by 3.8% in the fourth quarter. Millennium Management LLC now owns 387,921 shares of the company's stock worth $729,000 after buying an additional 14,164 shares during the last quarter. Jane Street Group LLC lifted its position in Protalix BioTherapeutics by 147.2% in the fourth quarter. Jane Street Group LLC now owns 113,616 shares of the company's stock worth $214,000 after buying an additional 67,664 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Protalix BioTherapeutics in the fourth quarter worth $192,000. 16.53% of the stock is currently owned by institutional investors.

Insider Activity at Protalix BioTherapeutics

In other news, Director Aharon Schwartz bought 129,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The stock was purchased at an average price of $1.60 per share, with a total value of $206,400.00. Following the completion of the acquisition, the director directly owned 303,000 shares of the company's stock, valued at $484,800. This trade represents a 74.14% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 12th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $15.00.

Protalix BioTherapeutics Stock Performance

PLX traded up $0.04 on Monday, hitting $1.58. The company had a trading volume of 57,737 shares, compared to its average volume of 822,160. Protalix BioTherapeutics, Inc. has a 12-month low of $0.98 and a 12-month high of $3.10. The stock has a market capitalization of $125.58 million, a price-to-earnings ratio of -12.04 and a beta of -0.23. The stock has a fifty day moving average price of $1.53 and a 200-day moving average price of $1.93.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.